Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129831 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study of COPD, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT00129831: Completed Phase 2 study of COPD, sponsored by Novartis.
NCT00129831 is a Phase 2 study of COPD that has completed, run by Novartis. The registered enrollment target is 6 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00129831, a Phase 2 study of COPD, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
Conditions Studied
Interventions
- DRUG QAB149
Study Locations (2)
California
- Radiant Research - Encinitas
Idaho
- Radiant Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00129831 record still lists
NCT00129831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 1 intervention - of which QAB149 is the first listed.
NCT00129831 reports a single indexed study location in California, Idaho.
Frequently Asked Questions
What is clinical trial NCT00129831 about?
NCT00129831 is a clinical study titled "Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
What is the current status of trial NCT00129831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2004-09. Estimated completion is 2005-09.
What conditions does trial NCT00129831 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT00129831?
The interventions under investigation include: QAB149 (DRUG).
Who is sponsoring clinical trial NCT00129831?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129831 being conducted?
This trial has 2 study locations across California, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00129831's enrollment target sits among peer trials
6 85th of 85 the lowest of 85 other COPD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
RECRUITING · Phase 2
-
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
RECRUITING · Phase 2
-
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
COMPLETED · Phase 2
-
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia